Literature DB >> 2010157

Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study.

Y F Liaw1, I S Sheen, T J Chen, C M Chu, C C Pao.   

Abstract

To investigate the incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection, a prospective follow-up study was conducted in two consecutive groups of patients. Group I consisted of 984 patients (859 men and 125 women) with biopsy-proven chronic type B hepatitis, whereas group II consisted of 1,598 asymptomatic chronic carriers (998 men and 600 women) with normal serum aminotransferase activity. During a mean follow-up period of 4.0 +/- 2.3 yr, 19 patients (1.9%) of group I cleared HBsAg from their serum, whereas 35 patients (2.2%) in group II did so in a mean follow-up period of 2.7 +/- 1.4 yr. The annual incidence of delayed serum HBsAg clearance was 0.5% in group I and 0.8% in group II (p less than 0.02). The cumulative probability of HBsAg clearance was also higher in group II than in group I (p less than 0.007). Antibodies to HBsAg developed in 9 patients (47.4%) with chronic hepatitis and in 11 (31.4%) asymptomatic carriers who cleared serum HBsAg. Those who were HBeAg negative and those older than 40 at entry and those who exhibited cirrhosis during follow-up had a higher incidence of delayed HBsAg clearance. Gender, initial histological changes and hepatitis delta virus infection did not influence the occurrence of HBsAg clearance. Serum HBV DNA was not detectable by slot-blot hybridization but was still detectable by polymerase chain reaction in serum specimens collected within 1 yr of HBsAg clearance. Liver biopsy performed later in 10 patients showed no significant hepatitis activity or tissue HBV DNA, HBsAg or HBcAg.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010157

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  57 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study.

Authors:  Cengiz Bolukbas; Fusun Filiz Bolukbas; Tulin Kendir; Nihat Akbayir; Ali Tuzun Ince; Evren Abut; Mehmet Horoz; Ali Remzi Dalay; Mehmet Haci Sokmen; Oya Ovunc
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

Review 3.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

Review 4.  Natural regression of fibrosis in chronic hepatitis B.

Authors:  Shogo Ohkoshi; Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Kenya Kamimura; Masahiko Yano
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

5.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

6.  Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.

Authors:  Yi-Cheng Chen; Chia-Ming Chu; Chau-Ting Yeh; Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2007-03       Impact factor: 6.047

Review 7.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

8.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

9.  HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Authors:  Tien Huey Lim; Edward Gane; Chris Moyes; Barry Borman; Chris Cunningham
Journal:  Hepatol Int       Date:  2016-03-08       Impact factor: 6.047

10.  Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.

Authors:  Chia-Ming Chu; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2012-08-18       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.